Masteron (drostanolone)
Muscle & Strength · Injectable DHT-derivative
Tier C
High-risk evidence profile
Bottom line
Read Off Label grades Masteron (drostanolone) as C (5.1/10) based on moderate evidence, med-high benefit magnitude, and a med-high-risk safety profile.
Its high-risk evidence profile reflects a Safety score of 3.5/10; reported benefits and harms can differ by indication, dose, route, duration, and population.
Originally developed as breast cancer treatment (Masteril).
Studied, labeled, or reported-use context: Propionate 100 mg EOD or enanthate 200-400 mg/week — Schedule III US; banned sport; not individualized guidance.
Citation correction in progress
1 PubMed link was found to be unrelated to this entry and removed from public output. The remaining sources are shown below, but this row's claims and score still need a full source-by-source revalidation.
What the evidence says
Originally developed as breast cancer treatment (Masteril). Bodybuilding use focused on pre-contest 'hardening' and anti-estrogenic synergy with other AAS. Strong androgenic effects disproportionate to anabolic — accelerates androgenetic alopecia.
Mechanism
DHT derivative; non-aromatizing; mild anti-estrogen activity (structural similarity to AI exemestane); primarily used for 'hardening' in lean cutting phases
Studied, labeled, or reported dose & route
Propionate 100 mg EOD or enanthate 200-400 mg/week
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Masteron (drostanolone)'s effects?
- Read Off Label rates the evidence for Masteron (drostanolone) as Moderate and the benefit magnitude as med-high, producing an overall grade of C (5.1/10). Originally developed as breast cancer treatment (Masteril).
- What safety findings are reported for Masteron (drostanolone)?
- Masteron (drostanolone) has a med-high risk profile in the database. Med-High (strong androgenic effects — hair loss in predisposed; aggression; HPG suppression; poor effect on lipids) Legal status: Schedule III US; banned sport.
- What does the low Safety score for Masteron (drostanolone) represent?
- The Safety score is 3.5/10. It records the substantial harms described for one or more use contexts; the Benefit score, indication, dose, route, duration, population, and legal status remain separate parts of the evidence profile.
- What doses or routes are reported for Masteron (drostanolone)?
- Propionate 100 mg EOD or enanthate 200-400 mg/week This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Masteron (drostanolone) work?
- DHT derivative; non-aromatizing; mild anti-estrogen activity (structural similarity to AI exemestane); primarily used for 'hardening' in lean cutting phases
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.